INTRODUCTION
Since the 1980s, investigators have described the recurrence of hemorrhagic stroke within families, manifesting as porencephalic cavities on computed tomography or magnetic resonance imaging (MRI). [1] [2] [3] [4] [5] [6] Before these observations, the presence of congenital porencephaly, a cyst that communicates with the lateral ventricle and is (usually) seen following parenchymal hemorrhage, had often been considered the result of an external insult, for example, postanoxic perinatal bleeding without genetic substrate and, in the absence of a coagulopathy, with low risk of recurrence. Only in 2005, after observations of mouse models, were COL4A1 mutations discovered as a cause of porencephaly, with an apparent autosomal dominant inheritance. [7] [8] [9] Over the years it became clear that disorders of additional organs can result from mutations in this gene. The disorder related to COL4A1 mutations is now known as a systemic disease, including a broad spectrum of cerebrovascular lesions: porencephaly and transmantle lesions, causing hydranencephaly or schizencephaly; lesions of the kidneys, leading to nephrosis and hematuria; lesions of the eyes, causing cataract, microphthalmia, and blindness; lesions of the heart, causing arrhythmia; and lesions of the skeletal muscles, causing dystrophic changes, weakness, and myoglobinuria. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] COL4A1 and COL4A2 encode proα1(IV) and proα2(IV) chains, respectively, which assemble to form a heterotrimeric helix with a constant 2:1 ratio (proα1(IV)) 2 (proα2 (IV)). This type IV collagen is a component of nonfibrillary collagen, a main constituent of the basement membranes of many tissues, among them vascular endothelia. COL4A1 and COL4A2 consist of three domains. The amino terminal 7S domain plays an important role in intermolecular cross-linking and macromolecular organization. The triple helical domain consists of a triple amino acid repeat sequence, Gly-Xaa-Yaa, where Xaa and Yaa can be any residue, although proline is the most frequent amino acid at the Yaa position. This sequence has several interruptions containing cysteine residues, which are important Submitted Two proα1(IV) chains, encoded by COL4A1, form trimers that contain, in addition, a proα2(IV) chain encoded by COL4A2 and are the major component of the basement membrane in many tissues. Since 2005, COL4A1 mutations have been known as an autosomal dominant cause of hereditary porencephaly. COL4A1 and COL4A2 mutations have been reported with a broader spectrum of cerebrovascular, renal, ophthalmological, cardiac, and muscular abnormalities, indicated as "COL4A1 mutation-related disorders. " Genetic counseling is challenging because of broad phenotypic variation and reduced penetrance. At the Erasmus University Medical Center, diagnostic DNA analysis of both COL4A1 and COL4A2 in 183 index patients was performed between 2005 and 2013. In total, 21 COL4A1 and 3 COL4A2 mutations were identified, mostly in children with porencephaly or other patterns of parenchymal hemorrhage, with a high de novo mutation rate of 40% (10/24) . The observations in 13 novel families harboring either COL4A1 or COL4A2 mutations prompted us to review the clinical spectrum. We observed recognizable phenotypic patterns and propose a screening protocol at diagnosis. Our data underscore the importance of COL4A1 and COL4A2 mutations in cerebrovascular disease, also in sporadic patients. Follow-up data on symptomatic and asymptomatic mutation carriers are needed for prognosis and appropriate surveillance.
Review in giving flexibility to the collagen IV network and providing possible binding sites for intermolecular cross-linking. The C-terminal NC1 domain is important in the initiation of triple helix formation. [23] [24] [25] Mice harboring heterozygous mutations in Col4a1 or Col4a2 suffer from hemorrhage in the eye, brain, and skin, which already occur during gestation and sometimes lead to developmental defects of the eye and brain. Therefore, similarities in phenotypes between COL4A1 and COL4A2 mutations were to be expected. In 2012 several parallel genetic, epidemiologic, and functional studies revealed COL4A2 mutations in both familial and sporadic porencephaly. [26] [27] [28] The disease resulting from both COL4A1 and COL4A2 mutations is extremely variable, with broad intra-and interfamilial variation and evidence for reduced penetrance. Sporadic individuals with severe presentation may harbor a de novo mutation.
At the Department of Clinical Genetics of the Erasmus University Medical Center in Rotterdam, the Netherlands, sequence analysis of both COL4A1 and COL4A2 has been offered in a diagnostic setting since 2005. This review summarizes the clinical and genetic data of mutations newly identified in the past 8 years. Although many reports of the mutation spectrum have been published, no clear recent guidelines regarding genetic counseling and management of affected patients exist.
Here we provide an up-to-date overview of the genotypic and phenotypic spectrum to improve clinical management and surveillance guidelines.
mATeRIALs AND meTHODs
At the Clinical Genetics Laboratory of the Erasmus University Medical Center in Rotterdam, 183 index patients (and whenever available both parents), mostly with cerebral hemorrhage or porencephaly, were referred for testing of COL4A1 (NM_001845.4) and COL4A2 (NM_001846.2). This was done by Sanger sequencing or by applying a next-generation sequencing panel encompassing 87 genes for brain developmental disorders, including genes for porencephaly and Aicardi-Goutières syndrome (capturing exons and intron-exon boundaries by eArray Sure Select (Agilent, Santa Clara, CA) and sequencing on the MiSeq platform (paired-end, 150 bp; Illumina, San Diego, CA), followed by confirmation of mutations with Sanger sequencing). A total of 21 COL4A1 and 3 COL4A2 putative pathogenic genomic variants were identified between 2005 and June 2013. We previously reported two of the COL4A2 and nine of the COL4A1 mutations. 7, 12, 15, 27, 29 From the families with the remaining 13 novel mutations, clinical data were collected using a questionnaire sent to the referring physicians according to the institutional review board regulations of our center.
Furthermore, we reviewed the literature, focusing on the clinical phenotypes of COL4A1 and COL4A2 mutations. For this, a PubMed search was performed, identifying 27 articles with clinical and mutation data on COL4A1 7, 8, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] and 3 articles with data on COL4A2 mutations. [26] [27] [28] A total of 137 individuals with a COL4A1 mutation from 60 families and 15 individuals with a COL4A2 mutation from 7 families have been reported. Several clinical phenotypes were identified and described in more detail. In addition, both neurologic and systemic features and brain MRI findings were available for review.
ResULTs mutation data on 13 newly identified families
Most COL4A1 and COL4A2 mutations reported in the literature are missense changes leading to a substitution of a glycine in the Gly-Xaa-Yaa triple helical domain. In analogy to other collagenopathies, these mutations are predicted to be pathogenic and are assumed to have a dominant-negative effect. In addition, splice-site mutations led to haploinsufficiency, and frameshift mutations have been reported, indicating that haploinsufficiency of either COL4A1 or COL4A2 is another pathogenic mechanism 27, 38 (Figure 1 ). COL4A1 and COL4A2 sequence variants in our cohort were considered pathogenic when de novo, when truncating, or when previously described and were proven to be pathogenic by de novo occurrence or functional studies. Most missense changes that were either predicted (ALAMUT package, http://www.interactive-biosoftware.com) or proven to be pathogenic disrupted the Gly-XaaYaa repeat of the triple helix.
In total, 21 COL4A1 mutations, 12 of them novel, and 3 COL4A2 mutations were identified. All the known COL4A1 and COL4A2 mutations, including those reported here, are depicted in Figure 1 . The pedigrees of the newly identified families are shown in Supplementary Figure S1 online.
Of the 12 cases associated with novel COL4A1 mutations, 5 were sporadic and de novo (Supplementary Figure S1 online; families D, E, H, I, and K) and 7 were familial. Of the seven familial mutations, the one in family B occurred de novo in patient I.1. Of the mutations in Supplementary Figure S1 online, only the COL4A2 mutation in family L was previously reported in a sporadic adult patient with intracerebral hemorrhage. 26 It introduces a glycine at the triple helical domain of the protein and was shown to be pathogenic using functional studies. 26 All but one of the COL4A1 mutation missense changes led to substitution of glycine in the triple helical domain of the protein (families A, B, C, G, H, I, K, and M). The changes in families A, C, G, and M have an official status of "variant of unknown clinical significance, " although they are likely pathogenic in view of their predicted effect on the protein. In addition, segregation with the phenotype has been observed in families A and C. In family E, a de novo missense mutation was present, affecting the NC1 domain. A de novo splice site mutation was identified in family D, and family G harbored an inherited frameshift mutation.
Clinical phenotypes identified in our cohort and in the literature
A total of 183 index patients were tested for COL4A1 and COL4A2 mutations. A diagnosis was possible in 24 of 183 of index patients (13%; published and unpublished), of which 10/24 (42%) were de novo. We identified 60 COL4A1 mutation Review families reported in the literature, of which 30 had an inherited mutation (50%); in 16 a de novo mutation was identified (27%), and in 14 cases (23%) the data on parental sequencing were lacking. For COL4A2 mutations, seven families were identified, of which three had an inherited mutation, one mutation was de novo, and in three cases data on parental carrier status were lacking.
The 12 novel COL4A1 families and 1 COL4A2 family in the present cohort comprise 21 individuals with a (suspected) pathogenic mutation. Of these, five (24%) developed signs antenatally, eight (38%) presented with signs soon after birth, three (14%) developed signs at a later age, and three (14%) have been clinically asymptomatic until now. Clinical data at onset are lacking for two patients (family G). Brain MRI has not been performed in these asymptomatic carriers until now, however, and brain damage cannot be fully excluded. Seizures were the most common clinical symptom, present in nine patients (43%). Also, a high percentage of motor dysfunction was present: hemiparesis in six (29%) and tetraparesis in three (14%). Developmental delay was present in eight cases (38%).
The clinical phenotypes and mutations of the newly identified families are summarized in Table 1 . A summary of the brain MRI findings, associated ophthalmological, renal, cardiac, and muscular findings, as well as incidentally reported findings in both our patients and those from the literature is provided in Table 2 . We provide an overview of several phenotypes observed in our cohort. The reported data on these phenotypes in the literature are discussed later, together with additionally reported phenotypes.
Prenatal and neonatal intracerebral hemorrhage and porencephaly
Porencephaly has been reported as a result of both COL4A1 and COL4A2 mutations, most often caused by germinal matrix hemorrhage leading to deep venous infarction with subsequent tissue necrosis and porencephalic cavitation. The first reports suggested an onset around birth, 8 whereas later reports also describe patients with an onset during late pregnancy. 12, 21, 29 In our cohort, 12 patients from 10 families (A, B, D, E, G, H, I, J, K, M) presented with early intracerebral hemorrhage and Recurrence of cerebral hemorrhage was documented in patient E-II.1, who presented with antenatal cerebral hemorrhage and porencephaly on antenatal brain MRI. She developed a severe hypoxic-ischemic encephalopathy, for which she received cooling therapy; she died soon after birth. Postmortem examination showed a novel parenchymal hemorrhage (Figure  2m,n) . Patient II.2 from family C had a congenital tetraplegia; however, data on brain imaging are lacking.
sporadic extensive bilateral porencephaly resembling hydranencephaly
Hydranencephaly is defined as the end result of massive hemispheric necrosis and extreme ventricular dilation, with most of the hemispheres replaced by a cerebrospinal fluid-filled membranous sac, and relative preservation of the diencephalic and posterior cranial fossa brain structures, with a variable onset, even starting in the first trimester. 41 In our cohort, patient II.1 from family H showed severe brain destruction with undetectable medial cerebral arteries, resembling hydranencephaly, at 33 weeks' gestation. The child was stillborn at 34 weeks of gestational age.
Periventricular leukomalacia with intracranial calcification
Periventricular leukomalacia (PVL) is defined as posthypoxic-ischemic leukoencephalopathy resulting from a pre-or perinatal hypoxic-ischemic insult. 42 PVL is characterized by focal periventricular necrosis and gliosis in the surrounding white matter. 43 Intracranial calcifications also are reported in this context. 14 In our cohort, patients A-I.2 and C-II.1 both show PVL without porencephaly (Figure 2b,e) . Brain calcifications were not present. Additional features in patient A-I.2 were congenital cataracts. Patient C-II.1 also showed ophthalmological features comprising microcornea, congenital cataract, and posterior embryotoxon. This combination, together with the family history, suggested the diagnosis in both patients.
Axenfeld Rieger anomaly with leukoencephalopathy
Axenfeld Rieger anomaly comprises a constellation of ocular findings affecting the anterior chamber, including the anterior chamber angle and aqueous drainage structures (iridogoniodysgenesis), iris hypoplasia, eccentric pupil, iris tears, and iridocorneal tissue adhesions traversing the anterior chamber. A frequent association consists of a posterior embryotoxon and a high risk of glaucoma and secondary blindness. In our newly reported family C, the three individuals with the COL4A1 change (C-I.2, C-II.1, C-II.2) were affected with similar ophthalmological findings from the Axenfeld Rieger spectrum: cataract and microcornea. The neurological symptoms, however, varied greatly, from absence in patient C-I.2, to PVL and normal cognition in patient C-II.1, to severe mental retardation and spastic hemiplegia in patient C-II.2.
Cortical malformations: schizencephaly
Although cortical lesions secondary to tissue necrosis have been described in COL4A1 mutations, 15 malformations of the cortex, in particular schizencephaly, have only been appreciated recently as being associated with COL4A1 mutations, 37, 39 Schizencephaly is defined as a cleft extending from the pial surface to the lateral ventricle, lined by heterotopic gray matter. 
Cardiac abnormalities

Raynaud 6
Cardiac (supraventricular) arrhythmia 4 1
Mitral valve prolapsed 4
Ventricular deptal defect 1
Other findings
Hemolytic anemia 5
Thymus, liver, and adrenal hemorrhage 1
Sensorineural deafness 1
a Numbers indicate patients reported in the literature and in present cohort. 
Review
In our cohort we observed two patients with focal cortical malformations. The first has a maternally inherited c.1964G>A (p.G655E) COL4A1 mutation and presented with schizencephaly, porencephaly, and intraventricular hemorrhage (patient H-II.1; Figure 2h) . The mother has a severe hypermetropia of +10 diopter. The second patient (L-II.1) has a paternally inherited c.3368A>G (p.E1123G) COL4A2 mutation and presented with porencephaly of the left frontal ventricle and an overlying dysplastic cortex resembling transmantle heterotopia on brain MRI (Figure 2l) . The father is asymptomatic, except for ptosis. The same COL4A2 mutation was previously reported in two adult patients with intraparenchymal hemorrhage; the mutation was proven to be pathogenic in in vitro functional studies. 26 
Previously unreported findings in our cohort
Patient II.1 from family K had a severe neonatal neurological presentation with seizures caused by intracerebral hemorrhages. At the age of 6 months he was diagnosed with neuroblastoma, which has not been previously associated with COL4A1 mutations but is a relatively frequent tumor in childhood. We mention this because of the occurrence of other neurological tumors in this cohort (meningioma in patient A-1.2 and in another COL4A1 carrier). 7 Neural tumors as part of the phenotypic spectrum does not seem likely based on these data, but certainty remains unclear.
The index patient from family J presented with a left-sided germinal matrix and intraventricular hemorrhage and posthemorrhagic venous infarction after birth. Interestingly, supraventricular tachycardia also was noted at this young age, requiring sotalol treatment. Whether the tachycardia is causally related to the COL4A1 mutation is unclear; however, it has also been reported in hereditary angiopathy with nephropathy, aneurysm, and muscle cramps (HANAC) syndrome. 16 
DIsCUssION
In this cohort, 183 index patients were tested. Patients were referred from different hospitals in the Netherlands and other European countries. For most of the patients, clinical data at referral were provided and mostly included brain imaging evidence of porencephaly or infantile hemorrhage. In total, we identified 21 COL4A1 and 3 COL4A2 pathogenic or likely pathogenic mutations. This suggests a high prevalence (13%) of mutations in this patient population. In the total cohort, a high percentage of de novo mutations was identified (42%; 10/24).
When reviewing the literature, a total of 67 families with COL4A1 and COL4A2 mutations were described. Among these families, 33 mutations (50%) were inherited; a de novo mutation was identified in 17 (25%), and in 17 cases (25%) the data on parental sequencing were lacking. These data support our finding that the de novo mutation rate in COL4A1 and COL4A2 is high.
The clinical data of 13 families are novel, and the 12 COL4A1 mutations have not been described previously. No clear genotype-phenotype correlation is present. In our novel families, a high percentage (60%; 12/20) of severe perinatal presentation was observed. In this respect, one must consider an ascertainment bias because the main indication for referral for COL4A1 and COL4A2 sequencing was porencephaly or infantile cerebral hemorrhage, that is, the best known phenotype of COL4A1 and COL4A2 mutations. Although the clinical phenotypes of our patients greatly overlap the phenotype previously reported in the literature, this study corroborates the phenotypic spectrum of the less commonly reported features ( Table 2) . We discuss the reported phenotypes in the literature in comparison with those in our patients in the following sections.
Prenatal and neonatal intracerebral hemorrhage and porencephaly
Porencephaly is one of the most frequently reported findings, described in 53 patients with COL4A1 mutations 7, 8, 12, 14, 15, 17, 18, 21, [37] [38] [39] and 6 patients with COL4A2 mutation 27,28 ( Table 2) . Because porencephaly was the first reported associated phenotype, however, there may be a bias in the inclusion of patients for COL4A1 and COL4A2 testing. Intraventricular hemorrhage is a common complication of preterm infants with a very low birth weight, and a group of 40 preterm infants was tested for the presence of COL4A1 mutations. Only one pathogenic mutation was identified. 10 This result indicates that COL4A1 mutations are probably only minor contributors to intraventricular hemorrhage in preterm infants with a very low birth weight. A recent report of COL4A1 screening in a group of 61 patients with porencephaly revealed mutations in 10 patients (16%) aged 3 months to 14 years. All these patients had additional features including focal cortical dysplasia, intracranial calcification, hemolytic anemia, elevated creatine kinase, myopathy, ophthalmological features, or hematuria. 39 A complication of the hemorrhage can be the development of secondary hydrocephalus, as seen in patient D-II.1 and previously reported. 13, 15, 45 sporadic extensive bilateral porencephaly resembling hydranencephaly
We previously described a subset of patients with extensive prenatal porencephaly and gray and white matter loss, cortical destruction, and cerebellar and brain stem atrophy, resembling hydranencephaly. A pathogenic mechanism, consisting of a massive germinal matrix hemorrhage followed by extensive venous infarction with compression, edema, and secondary ischemia of larger parenchymal areas and leading to white matter and cortical destruction, was suggested. Interestingly, we found de novo COL4A1 mutations in all these patients, including a case of germ-line mosaicism in the mother of one patient.
15
PVL with intracranial calcification
Subtle periventricular, basal ganglia, and/or deep white matter calcifications are reported in COL4A1 mutations, together with PVL, also in the absence of porencephaly. 14, 33, 37, 39, 46 The diagnosis in patients with this PVL phenotype without a contributing family history or additional findings could easily be missed. Associated features, such as elevated creatine kinase concentration or microbleeds, may help in suspecting the diagnosis in the absence of other major findings such as porencephaly. 14, 33, 37, 39 These associated findings may also help in discriminating COL4A1-related calcifications and leukoencephalopathy from disorders with partially overlapping manifestations, such as Aicardi-Goutières syndrome, classically characterized by infantile encephalopathy, cerebral calcifications, cerebral atrophy, and leukodystrophic white matter changes, 47 as well as cytomegalovirus infection or cystic leukoencephalopathy, without megalencephaly. 14, 48 Axenfeld Rieger anomaly with leukoencephalopathy Axenfeld Rieger anomaly, as well as cataracts, microcornea, and retinal detachment, have been reported as consistent findings in several other families harboring COL4A1 mutations. Although major cerebral findings such as porencephaly or hemorrhagic stroke can be present, all patients showed leukoencephalopathy and small-vessel disease, even in the absence of neurological symptoms. This indicates that brain MRI in patients with Axenfeld Rieger anomaly may provide a clue for the diagnosis of a COL4A1-related disorder.
11,18
HANAC syndrome
The HANAC syndrome comprises a specific combination of features and is attributed to mutations in COL4A1 affecting glycine residues in close proximity of exons 24 and 25, reported to be the triple helical CB3[IV] domain, encompassing major integrin binding sites. 16, 32, 35 The angiopathy in HANAC syndrome comprises retinal vessel arterial tortuosity and cerebral small-and large-vessel disease with aneurysms of the carotid syphon. The nephropathy consists of persistent hematuria and/ or proteinuria with or without bilateral large renal cysts. Other associated findings are muscle cramps with elevated creatine kinase concentrations, Raynaud phenomenon, and cardiac arrhythmia. Interestingly, patients with HANAC syndrome do not present with infantile hemiplegia or porencephaly. Also, the risk of major (hemorrhagic) stroke is thought to be lower than in other COL4A1 mutations. 16, 32, 35 In our cohort, no patients displaying the HANAC phenotype were identified, possibly because of referral bias, since our cohort comprises mostly neurological patients. The clinical picture of HANAC is possibly insufficiently known by referring physicians to be associated with COL4A1 mutations.
stroke in childhood and young adulthood
In addition to prenatal hemorrhage leading to porencephaly, strokes in the form of cerebral bleeding at a later age can occur with COL4A1 and COL4A2 mutations. 17, 20, 31, 34 Stroke in later childhood and young adulthood was not reported in our cohort. In the literature, cerebral hemorrhages in childhood or in young adulthood have been documented in patients with COL4A1 mutations. Differential diagnostic considerations in these cases comprise other genetic cerebrovascular malformation syndromes, such as cerebral cavernous hemangiomas or hereditary hemorrhagic telangiectasia. Hemorrhagic strokes Review typically affect the deep white matter, in combination with diffuse leukoencephalopathy and microbleeds. 17, 20, 31, 34 Recurrence of strokes has been reported. 20, 31 Two of the documented cases were sporadic, 20,34 the others were familial. 17, 31 sporadic late-onset hemorrhagic stroke
Sporadic intracerebral hemorrhage generally occurs in the elderly, with a worldwide incidence of 24.6 per 100.000 personyears, 49 frequently in the setting of risk factors such as cerebral amyloid angiopathy or hypertensive vasculopathy, alcohol consumption, or cigarette smoking.
In our cohort, patients with adult-onset cerebral hemorrhage are lacking. This may very well be due to selection bias, probably because most patients were referred by clinical geneticists and neonatologists because of pre-and perinatal hemorrhage or porencephaly.
In a cohort of 96 sporadic patients with intracerebral hemorrhage not caused by arteriovenous malformations, tumors, or impaired coagulation, COL4A1 and COL4A2 were tested, leading to the detection of two COL4A1 mutations in two patients and three COL4A2 mutations in four patients. 22, 26 These findings indicate that COL4A1 and COL4A2 mutations contribute to ~6% of sporadic late-onset intracerebral hemorrhage. Because intracerebral hemorrhage constitutes ~15% of all intracranial hemorrhages in this group of patients, the contribution of COL4A1 and COL4A2 mutations to the total group of intracranial hemorrhage is ~1%. Although the portion may seem small, the general prevalence of COL4A1 and COL4A2 mutations may be quite high; intracerebral hemorrhage in the elderly is not a rare event. The mutations identified in the patients are missense mutations, which probably have a milder effect on collagen IV function, and not the frequently identified triple helical domain glycine changes. 22, 26 However, the pathogenicity of these milder missense mutations has only been tested in an in vitro expression system.
Focal cortical dysplasia and schizencephaly
In the literature, COL4A1 mutations were identified as the first genetic cause of schizencephaly 37, 39 ; mutations were found in 5 of 10 patients with schizencephaly who were tested. We describe the first patient with cortical dysplasia harboring a COL4A2 mutation (L-II.1). The localization of the cortical dysplasia and the association with an underlying porencephalic enlargement of the frontal part of the lateral ventricle in our patient suggest a causal relation between the COL4A2 mutation and the cortical malformation (Figure 2l) . Interestingly, the father also carries the mutation and is asymptomatic, but no MRI has been performed. The pathogenesis of this malformation is probably similar to that of the schizencephaly and hydranencephaly reported in COL4A1 mutations. Our findings indicate that COL4A2 mutations can also lead to dysplastic cortex, thereby broadening the COL4A2 phenotypic spectrum. The role of COL4A2 mutations in cortical dysplasia associated with porencephaly needs to be investigated in a larger patient cohort.
Issues in genetic counseling and management of affected families
There are several plausible, non-mutually exclusive pathogenic mechanisms of various COL4A1 and COL4A2 mutations, which were summarized in a recent review. 25 The pathogenic mechanism is still not elucidated completely and may be different depending on mutation type.
Another unresolved question is the matter of the reduced penetrance. The same mutation can lead to a severely affected infant, while the carrier parent is hardly affected. This leads to the hypothesis that COL4A1 and COL4A2 mutations must be regarded as risk factors that, together with additional modifying factors, lead to a phenotype. Mouse models support this hypothesis, showing that penetrance and disease severity is related to the genetic context. 13, 50 Because of the reduced penetrance with possible modifying factors and the variable phenotype, the counseling of affected patients and their families remains a challenge. We suggest an initial workup in families with a mutation, including neurological, ophthalmological, renal, and cardiac screening in mutation carriers and first-degree relatives with a 50% chance of harboring the mutation (the latter taking into account the social consequences of presymptomatic DNA testing) ( Table 3) . Neurological screening should include a medical history and physical examination, followed by brain MRI if abnormalities are found. We recommend adding susceptibility-weighted imaging because it improves the detection of microbleeds. 51 Performing magnetic resonance angiography to identify cerebral aneurysms is still under debate; to date no ruptured aneurysms have been reported in mutation carriers, suggesting a slow progression rate and discouraging the use of magnetic resonance angiography. Follow-up data on the course of aneurysms identified in this specific group of patients, however, are lacking.
Another subject under debate is the perinatal management of pregnancies in which the child or the mother harbors a COL4A1 or COL4A2 mutation. Prenatal testing can be offered in highrisk pregnancies after genetic counseling, with special attention given to the variable phenotypic expression and reduced penetrance. Caesarean delivery has been proposed to prevent brain vascular injury attributable to birth trauma. 30 Evidence that this will lead to the prevention of cerebral hemorrhage is lacking, however, and several patients who had lesions established long before delivery have now been reported. 12, 15, 21, 29, 36 Further studies Review of the clinical course of individuals with COL4A1 or COL4A2 mutations are needed to determine the follow-up in more detail.
Conclusions
Our data confirm that COL4A1 and COL4A2 mutations are important causes of cerebrovascular disease with a high mutation detection rate in porencephaly and childhood cerebral hemorrhage with a relatively high rate of de novo mutations. Although also present in (sporadic) adult-onset intracerebral hemorrhage, with an incidence of 6%, 22, 26 the role of mutations in this patient cohort seems less prominent. It seems important to increase awareness of this disorder among neurologists and internists coping with the adult population. In addition to the cerebrovascular phenotype, systemic involvement with ocular, renal, muscular, and cardiac features must not be underestimated and needs to be screened at diagnosis, even outside the formal HANAC syndrome. The precise role of COL4A1 and COL4A2 mutations in cortical malformations needs to be elucidated, but it seems to contribute to those malformations that are most likely a result of a vascular insult during fetal development. 52 Follow-up data on COL4A1 and COL4A2 mutation carriers are important to develop appropriate surveillance protocols and adapt treatment.
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